Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac care solutions, has scheduled its Q2 2025 earnings conference call for August 13, 2025, at 4:30 p.m. Eastern time. The call will be led by CEO Robert Eno and CFO Timothy Cruickshank, who will discuss second quarter results and provide updates on regulatory initiatives and commercial activities.
The earnings release will be issued before the call, which will include a presentation accessible through the company's investor relations website. Participants can join via phone using U.S. dial-in 1-844-826-3035 or international dial-in 1-412-317-5195 with conference code 10201583. A webcast will also be available, and a replay will be accessible until November 13, 2025.
HeartBeam (NASDAQ: BEAT) has been awarded the Innovation Award in Remote Cardiac Diagnostics at the 2025 Medical Device Network Excellence Awards for its groundbreaking FDA-cleared ECG technology. The company's proprietary technology captures heart electrical signals in 3D non-coplanar directions and synthesizes them into a 12-lead ECG using a credit card-sized, cable-free device.
The technology enables clinical-grade diagnostics for arrhythmia assessment outside traditional healthcare settings, allowing patients to record symptoms as they occur. HeartBeam's 12-lead ECG synthesis software is currently under FDA review, with commercialization planned upon clearance. The company has previously received multiple industry recognitions, including the Pinnacle Healthcare Award and MedTech Breakthrough Award.
- Strategic collaboration with AccurKardia to enhance arrhythmia assessment capabilities
- Raised $11.5M through public offering in February 2025
- Added two new US patents, now owning 20 issued patents globally
- Cash position of $8.2M as of March 31, 2025
HeartBeam (NASDAQ: BEAT) has secured two new U.S. patents, strengthening its intellectual property portfolio in cardiac monitoring technology. The first patent protects their credit card-sized, cable-free 3D ECG device with chest and finger electrodes that capture high-fidelity electrical signals in three non-coplanar directions. The second patent covers their rhythm analysis algorithm for distinguishing between various heart rhythms using continuous signal input, designed for integration with wearable devices.
The company's 12-lead ECG synthesis software is currently under FDA review, supported by data from the VALID-ECG pivotal study presented at the Heart Rhythm Society conference in April 2025. HeartBeam now holds 20 issued patents worldwide, with 2 allowed patents and 32 pending patents, positioning itself as a leader in cardiac monitoring innovation.
HeartBeam (NASDAQ: BEAT) has appointed CEO Robert Eno to its Board of Directors, expanding from eight to nine members. Eno, who joined as President in January 2023 and became CEO in October 2024, brings over 30 years of medical technology industry experience. The company received FDA clearance for its 3D ECG technology in December 2024 and submitted an FDA application for its 12-lead ECG synthesis software in January 2025.
HeartBeam's technology captures heart electrical signals in 3 non-coplanar directions and synthesizes them into a 12-lead ECG. The company has initiated an Early Access Program to gather feedback on clinical workflow and establish early adopters. Prior to HeartBeam, Eno served as CEO of Preview Medical and held leadership roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular.
HeartBeam (NASDAQ: BEAT) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, May 13, 2025, at 4:30 p.m. Eastern time. The call will be hosted by CEO Robert Eno and CFO Timothy Cruickshank, who will discuss Q1 2025 results, regulatory initiatives, commercial-readiness activities, and anticipated milestones. A detailed press release will be issued before the call.
The conference call will include a presentation accessible during the webcast and afterward through the company's investor relations website. A replay will be available for three months until August 13, 2025, through both domestic (1-844-512-2921) and international (1-412-317-6671) dial-in numbers.
HeartBeam has achieved a significant breakthrough in cardiac care technology, announcing successful clinical endpoints in its VALID-ECG pivotal study for its synthesized 12-lead ECG technology. The study, presented at the Heart Rhythm Society's conference in San Diego, demonstrated a 93.4% overall diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment.
The company's innovative solution uses a credit card-sized device featuring patented 3D ECG technology that captures heart electrical signals in 3 non-coplanar directions. These signals are then transformed into a 12-lead ECG using a personalized matrix.
Key highlights:
- FDA application submitted in January 2025 for the 12-lead ECG synthesis software
- Early Access Program launched to gather clinical workflow feedback
- Multicenter trial conducted across 5 major US clinical sites with 198 patients
- Participating institutions include Allegheny Health Network, Mount Sinai Hospital, and Piedmont Heart Institute
The company plans to begin commercialization upon receiving FDA clearance.
HeartBeam (NASDAQ: BEAT) has announced a strategic collaboration with AccurKardia to advance cardiac monitoring innovation. The partnership will integrate AccurKardia's FDA-cleared ECG analysis software, AccurECG™, into HeartBeam's devices.
HeartBeam's innovative technology features a credit card-sized, cable-free 3D ECG device that captures heart signals in 3 non-coplanar directions and converts them into a 12-lead ECG using a personalized transformation matrix. The company plans to begin commercialization after receiving FDA clearance for the 12-lead ECG synthesis software.
The collaboration aims to enhance cardiac monitoring accessibility by combining HeartBeam's device with AccurKardia's automated ECG interpretation platform, enabling faster diagnosis and improved access to clinical care. This partnership is expected to accelerate HeartBeam's product development while reducing costs and timelines.
HeartBeam (NASDAQ: BEAT) reported its Q4 and full year 2024 results, marking significant milestones in cardiac care technology. The company received FDA 510(k) clearance for its HeartBeam System for arrhythmia assessment and launched an Early Access Program. They also submitted a 510(k) application for their 12-lead ECG synthesis software.
Financial highlights include securing $11.5 million in gross proceeds from a public offering. Q4 2024 showed R&D expenses of $2.9M (vs $2.0M in Q4 2023) and G&A expenses of $2.1M. The company reported a net loss of $4.9M for Q4 2024 and $19.4M for the full year. Cash position stood at $2.4M as of December 31, 2024.
Clinical progress includes presenting positive results at the American Heart Association conference, demonstrating comparable performance between HeartBeam's synthesized 12-lead ECG and standard ECGs for arrhythmia detection.